SBIR/STTR Research Award
Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS
Award amount
$225,000Program and phase
STTR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- FOX CHASE CHEMICAL DIVERSITY CENTER INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- V6EQM9ABEM89
- Solicitation number
- PA13-235
- Topic code
- NIGMS
Research abstract
DESCRIPTION: While HIV/AIDS can be managed with antiretroviral drugs that block viral replication, these agents do not clear the virus and require life-long drug administration with associated risks of cumulative toxicity and drug resistance. Recently, wediscovered a completely new class of compounds that interfere with the HIV-1 virulence factor, Nef. This viral protein is critical to HIV-1 replication in vivo, immune escape of HIV-infected cells, and AIDS progression. Nef antagonists have the potential to synergize with current antiretroviral drugs, thereby reducing toxicities and the risk of drug resistance. Nef inhibitors may also restore immune recognition of HIV-infected cells, potentially clearing the virus. Our lead Nef inhibitors are based on a diphenylpyrazolodiazene (DPP) scaffold that binds directly to the HIV-1 Nef protein and blocks its myriad functions in vitro. The goal of this Phase I STTR grant application, therefore, is to exploit our discovery of novel HIV Nef inhibitors through the
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Combinations of Oral Antibiotics to Treat Syphilis
- Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum
- Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle
- Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
- Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Three-Dimensional Spatio-Temporal Control of Lipid Nanoparticle Manufacturing for Improved Nucleic Acid Delivery
- Paradigm-changing, versatile, scalable and cost-effective technology for monthly injections of peptide drugs
- Project MATCH: Multi-spectral AI/ML powered Burn and Wound Evaluation Technology using a Cost-Effective Handheld Device.
- A versatile platform to isolate cells from three-dimensional samples after spatial and temporal profiling
- Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States
Research funding history
38 SBIR/STTR records share this UEI (2009–2025). Reported award amounts total $42,025,779. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services